Released May 12, 2022, after the close
10-Q filed May 12, 2022, 42 days after period end · 0001564590-22-019879
Q1 2022 · 10-Q
Revenue—
Net Income-$23.09M-$23.09M N/M vs Q1 2021N/M vs Q4 2021
EPS Diluted-$0.48-$0.48 N/M vs Q1 2021no prior Q4 2021 on file
Operating Income-$23,162,000N/M
Operating Cash Flow-$27,502,000N/M
Free Cash Flowderived-$27,502,000N/M
What the release said
The release
Same quarter
| Metric | Q1 2022 | Q1 2021 | Q1 2020 | Q1 2019 |
|---|---|---|---|---|
| Revenue | — | — | $4.08M | $3.89M |
| Net Income | -$23.09M | -$27.20M | -$26.66M | -$27.05M |
| EPS Diluted | -$0.48 | -$0.69 | -$0.76 | -$1.05 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Assembly Biosciences, Inc. · CIK 1426800 · Engraved from SEC EDGAR